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(47.9% vs. 45.1%), and to have hypercholesterolemia (55.0%
vs. 51.5%) than women who had not used HRT (p .001).
However, they were less likely to have diabetes (8.6% vs.
10.1%, p .001). Despite the increased prevalence of several
atherosclerotic risk factors among women who used HRT,
they were significantly less likely to have PAD (3.3% vs. 4.1%,
p.001).Multivariate analysis confirmed thatHRTwas inde-
pendently associated with a decreased risk of PAD (OR 0.8,
95% CI 0.78-0.82). In postmenopausal women with existing
risk factors, the significant effect of HRT on the prevalence
PADwasmaintained: in postmenopausal womenwith either a
smoking history, hypertension, hypercholesterolemia, or dia-
betes, the odds ratio of HRT use with regard to PAD re-
mained 0.8.
Conclusions: The use of HRT in postmenopausal
women is associated with a significant reduction in the
prevalence of PAD. This association was significant even in
postmenopausal female patients with known atheroscle-
rotic risk factors. This data has important implications with
regard to a possible protective effect of HRT on atheroscle-
rotic conditions, particularly in patients at higher risk for
these conditions due to medical co-morbidities.
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Objectives: The operative mortality of complicated type
B aortic dissection (CTBAD) is reported to be as high as
30%. The use of endografts in the treatment of CTBAD is
well described. However, significant questions still remain
on timing, patient selection, anatomical limitations, treat-
ment length and device performance. With these questions
in mind, the objective of this study was to evaluate the
safety and effectiveness of a unique composite (proximal
stent graft and distal bare metal stent) TEVAR construct in
the treatment of patients with CTBAD.
Methods: For this prospective, single-arm, interna-
tional study, patients with CTBAD were treated with a
combination of proximal endovascular thoracic grafts and
distal bare endovascular stents. Indications for enrollment
were malperfusion of visceral organs, impending rupture,
aortic diameter 4 cm, rapid aortic expansion, persistent
uncontrollable pain or hypertension despite maximum
medical therapy. Study endpoint was mortality at 30 days.
One year follow-up with scheduled clinical and radio-
graphic (CT and X-ray) were available.
Results: Ten centers enrolled 40 patients between
12/2007 and 9/2009. The majority of patients were male
(28,70%) and the mean age was 58 years. All patients had
multiple specific indications for treatment (31,77.5% im-
pending rupture/malperfusion), and the mean time
from presentation to treatment was 20 days (range
0-78). All devices were successfully deployed and patent.
The 30-day mortality rate was 5% (2). Thirty-day mor-
bidity included stroke (4,10%), paraplegia (1,2.5%), aor-
tic rupture (1,2.5%) and renal failure (5,12.5%). No pa-
tient became dialysis dependent. No conversions to open
surgery, issues with device integrity, or stentmigration have
been observed.
Conclusions: Initial data with a composite TEVAR
construct have demonstrated favorable clinical and ana-
tomic results. Continued enrollment and long-term data
are needed to assess the overall effectiveness of this treat-
ment strategy.
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Objectives: Neuromonitoring of spinal function by de-
tecting motor evoked potentials (MEPs) during open repair
(OR) of thoracoabdominal aortic aneurysms (TAAA) is a
valid method to assess insufficient arterial supply to alpha
motor neurones. This method requires a complex tech-
nique and specific neurophysiological expertise. We dem-
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